Diabetes Mellitus News and Research

RSS
Diabetes mellitus is a severe and debilitating chronic disease that develops in nearly 5 percent of the world’s population. People with this disease have a shortage of insulin or a reduced ability to use insulin, the hormone regulating blood glucose levels, which is normally produced by the pancreas. In the United States alone, an estimated 18 million people have diabetes, and each year about 1 million Americans are diagnosed with the disease. It is the sixth leading cause of death in the US and is responsible for over 200,000 deaths a year. Insulin-dependent (type I) diabetes accounts for around 10% of diabetics. For those patients, suffering from an inability of their pancreas to produce insulin, the only practical treatment possible is regular insulin replacement by multiple daily injections. Transplantation of a pancreas or pancreatic tissue would be beneficial to millions of such patients in that it would restore their normal ability to produce self insulin. Transplantation of human pancreas or pancreatic islets is a practiced and time-honored such therapeutic approach, but is extremely limited by the severe shortage of human donor organs. Tissera's R&D efforts in this domain are directed towards the development of a universally available and reliable source of animal fetal donor pancreatic precursor tissue, suitable for transplantation and eventual normal structural and functional growth in human diabetics.
Compugen discovers new biomarker for predisposition to type 2 diabetes using its GeneVa platform

Compugen discovers new biomarker for predisposition to type 2 diabetes using its GeneVa platform

Obese lung cancer patients with diabeties more likely to develop chest wall pain after receiving stereotactic body radiation therapy

Obese lung cancer patients with diabeties more likely to develop chest wall pain after receiving stereotactic body radiation therapy

FDA update on BYETTA injection: Amylin Pharmaceuticals and Eli Lilly respond

FDA update on BYETTA injection: Amylin Pharmaceuticals and Eli Lilly respond

Pico-Tesla commences pilot study of its Resonator system for treating type 2 diabetes patients

Pico-Tesla commences pilot study of its Resonator system for treating type 2 diabetes patients

FDA approves an expanded indication for BYETTA injection

FDA approves an expanded indication for BYETTA injection

CCS updates the Canadian guidelines for the management and treatment of dyslipidemia

CCS updates the Canadian guidelines for the management and treatment of dyslipidemia

Roche discloses the results of first Phase III clinical study using Taspoglutide

Roche discloses the results of first Phase III clinical study using Taspoglutide

Arena Pharmaceuticals presents data from its Phase 3 trial of LOrcaserin

Arena Pharmaceuticals presents data from its Phase 3 trial of LOrcaserin

Consumer health informatics applications help patients to better manage their health care

Consumer health informatics applications help patients to better manage their health care

GI Dynamics’ EndoBarrier Gastrointestinal Liner for pre-surgical weight loss treatment demonstrates safety

GI Dynamics’ EndoBarrier Gastrointestinal Liner for pre-surgical weight loss treatment demonstrates safety

Heart attacks in middle-aged women more common, says study

Heart attacks in middle-aged women more common, says study

Boehringer Ingelheim receives European CHMP positive opinion for MICARDIS

Boehringer Ingelheim receives European CHMP positive opinion for MICARDIS

Liraglutide drug causes less nausea and hypoglycaemia compared to exenatide

Liraglutide drug causes less nausea and hypoglycaemia compared to exenatide

Bristol-Myers Squibb reports strong sales and earnings growth for third quarter 2009

Bristol-Myers Squibb reports strong sales and earnings growth for third quarter 2009

Dose optimization data from Tolerx's Phase 2 clinical study of otelixizumab

Dose optimization data from Tolerx's Phase 2 clinical study of otelixizumab

New diabetes algorithm released by AACE for the management of type 2 diabetes

New diabetes algorithm released by AACE for the management of type 2 diabetes

New results from ADVANCE provide important insights to reduce diabetes complications

New results from ADVANCE provide important insights to reduce diabetes complications

Wellstat Therapeutics and Sanofi-Aventis to develop, manufacture and commercialize PN2034

Wellstat Therapeutics and Sanofi-Aventis to develop, manufacture and commercialize PN2034

Novo Nordisk's Levemir not associated with increase in the incidence of cancer

Novo Nordisk's Levemir not associated with increase in the incidence of cancer

Phase 3 clinical trial of macimorelin (AEZS-130) to be completed by AEterna Zentaris

Phase 3 clinical trial of macimorelin (AEZS-130) to be completed by AEterna Zentaris

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.